Bristol-Myers Squibb: stocks, financial statements

Disable ads for free
Dividends News
Favorites

Bristol-Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It includes chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

  • BMY Ticker
  • NYSE Exchange
  • 23,300 Employees
18 rated
  • $66.77, $-0.15 (-0.22%) Previous Close
  • 8,840,857 Previous Volume
  • $53.07 / $67.96 52 week low / high
  • -1.75% Percent off 52 week high
  • 2021-06-17 Updated
  • 2.82% Dividend Yield (trailing)
  • 2.94% Dividend Yield (forward)
  • 0 Public float
  • 2,232,843,755 Outstanding shares
  • -24.03 P/E
  • 149.42 B Market Cap
Disable ads for free

Financial statements — Bristol-Myers Squibb

The information is not 100% up-to-date. There may be errors or missing information. Some information is often missing, and, although there are almost no errors, I can't rule them out. Right now, I'm looking for a supplier of high-quality information, but so far what I'm finding is expensive (about $2000 a year). You can help my project here.
20 ← 16 2020 2019 2018 2017 2016
Total Revenue
43B 26B 23B 21B 19B
Cost Of Revenue
12B 8.1B 6.5B 6.1B 4.9B
Gross Profit
31B 18B 16B 15B 14B
Research and Development
11B 6.1B 6.3B 6.4B 4.9B
Selling General and Admin
7.7B 4.9B 4.6B 4.7B 4.9B
Operating Expense
40B 20B 17B 17B 15B
Operating Income
2.2B 5.9B 5.1B 3.6B 4.6B
Other Income Expense Net
0 0 0 0 0
EBIT
2.2B 5.9B 5.2B 3.7B 4.7B
Interest Income
1.4B 660M 180M 200M 170M
Pretax Income
-6.9B 5B 6B 5.1B 5.9B
Income Tax
2.1B 1.5B 1B 4.2B 1.4B
Minority Interest
20M 21M 27M -32M 50M
Net Income
-9B 3.4B 4.9B 1B 4.5B
Net Income Basic
-9B 3.4B 4.9B 1B 4.5B
20 ← 16 2020 2019 2018 2017 2016
Current cash
16B 15B 8.9B 6.8B 6.4B
Short term investments
3.2B 2B 1.1B 580M 570M
Receivables
8.5B 7.7B 6B 6.3B 5.5B
Inventory
2.1B 4.3B 1.2B 1.2B 1.2B
Other current assets
3.2B 2B 1.1B 580M 570M
Current assets
30B 29B 17B 15B 14B
Long term investments
88B 100B 18B 19B 20B
Property plant equipment
5.9B 6.3B 5B 5B 5B
Goodwill
21B 22B 6.5B 6.9B 6.9B
Intangible assets
53B 64B 1.1B 1.2B 1.4B
Other assets
1.7B 2.1B 2B 1.5B 1B
Total assets
120B 130B 35B 34B 34B
Accounts payable
2.7B 2.4B 1.9B 2.2B 1.7B
Current long term debt
2.3B 3.3B 1.7B 990M 990M
Other current liabilities
14B 13B 7.1B 6.3B 6.2B
Total current liabilities
19B 18B 11B 9.6B 8.8B
Long term debt
48B 43B 5.6B 7B 5.7B
Other liabilities
6.6B 9.1B 4.6B 5.2B 2.8B
Minority Interest
60M 100M 96M 110M 170M
Total Liabilities
81B 78B 21B 22B 18B
Common stock
2.3B 1.7B 1.6B 1.6B 1.7B
Retained earning
21B 34B 34B 31B 34B
Treasury stock
-26B -25B -20B -19B -17B
Capital surplus
Shareholder equity
38B 52B 14B 12B 16B
Net tangible assets
-36B -35B 6.4B 3.7B 7.9B
20 ← 16 2020 2019 2018 2017 2016
Net Income
-9B 3.4B 4.9B 1B 4.5B
Depreciation
10B 1.7B 640M 790M 380M
Changes in receivables
820M 1.7B -340M 760M 1.2B
Changes in inventories
-2.2B 3.1B 29M -75M 20M
Cash change
1.1B 6.5B 2.1B 460M 2.1B
Cash flow
14B 8.1B 5.9B 5.3B 2.9B
Capital expenditures
-750M -840M -950M -1.1B -1.2B
Investments
Investing activity other
Total investing cash flows
-11B -9.8B -870M -66M 1.5B
Dividends paid
Net borrowings
31B 29B -2.7B 570M -210M
Other financing cash flows
Cash flow financing
-1.2B -7.6B -3.5B -4.1B -2.4B
Exchange rate effect